Tenaya Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Three clinical-stage programs are advancing efficiently, with TN-301 showing broad preclinical efficacy and TN-201 and TN-401 progressing in gene therapy trials. The Alnylam partnership adds significant capital and pipeline depth, while upcoming data and regulatory milestones are expected to drive further value.
Fiscal Year 2025
-
Initial results from the RIDGE-1 trial show TN-401 gene therapy is well tolerated and demonstrates robust molecular and early clinical efficacy in PKP2-associated ARVC, with significant reductions in arrhythmia burden and increased PKP2 protein levels. Data compare favorably to peers and support further development.
-
Interim data from the TN-201 MyPEAK-1 trial show robust gene expression, improved cardiac biomarkers, and significant reductions in hypertrophy and heart failure symptoms in severe HCM patients. The FDA-requested protocol amendments are minor, with no impact on timelines, and future pivotal studies remain on track for 2026.
-
Cardiac gene therapy is advancing with novel capsids, improved manufacturing, and regulatory support, targeting both rare and prevalent diseases. Companies are focusing on safety, commercial readiness, and precision medicine, with optimism for upcoming clinical and commercial milestones.
-
Two AAV9-based gene therapies, TN-201 and TN-401, are advancing in clinical development for severe genetic cardiomyopathies, with TN-201 showing promising interim results in refractory HCM patients and TN-401 set for initial data release in Q4. Robust protein quantification and careful data disclosure support their competitive positioning.
-
Significant progress was reported for both TN-201 and TN-401 gene therapy programs, with all milestones met and major data updates expected in Q4, including a late-breaker AHA presentation. The regulatory environment remains favorable, safety protocols are robust, and innovative approaches in protein measurement and AI-driven discovery are advancing the pipeline.
-
The event detailed advances in gene therapy for genetic cardiomyopathies, emphasizing the use of mass spectrometry for precise protein quantification. Early clinical data show promising safety and efficacy signals, with further data expected to guide dose selection and future development.
-
The company is advancing gene therapies for two major genetic heart diseases, with promising early safety and efficacy data and pivotal study planning underway. Q4 will bring key updates for both TN-201 and TN-401, while the small molecule TN-301 awaits further development opportunities.
-
Genetic medicine programs are advancing with strong regulatory momentum and over $100 million in cash to fund key clinical milestones. TN-201 and TN-401 gene therapies are on track for major data readouts, while the TN-301 small molecule is being positioned for partnership.
-
Two gene therapy programs for genetic cardiomyopathies are advancing, with strong early safety and efficacy signals, robust manufacturing, and a solid financial position. Key data readouts and potential pivotal study transitions are expected over the next 12-15 months.
Fiscal Year 2024
-
Initial results from the MyPEAK-1 trial show TN-201 gene therapy is well tolerated, with robust cardiac delivery, increasing RNA and protein expression, and early signs of clinical stabilization or improvement in severe MYBPC3-associated HCM patients. Cohort two dose escalation is underway, with more data expected in 2025.
-
The conference highlighted progress on two gene therapy programs for HCM, with initial clinical data for TN-201 expected later this year and TN-401 set to begin dosing. The focus is on addressing unmet needs in non-obstructive HCM, with a robust clinical strategy and safety measures in place.
-
Significant market opportunities exist for gene therapies targeting MYBPC3 and PKP2 mutations, with initial TN-201 phase 1b data expected in the second half of the year. Accelerated approval is possible, especially for severe pediatric cases, and preclinical data support the use of AAV9 capsid.